A Systematic Review of Health-Related Quality of Life Outcomes in Patients With Advanced Breast Cancer Treated With Palbociclib

September 2024 in “ Journal of Comparative Effectiveness Research ”

Imtiaz A. Samjoo, Alexandra Hall, Connie Chen, Nguyen Bao Ngoc, Meaghan Bartlett, Mary Lou Smith, Nadia Harbeck, Joseph C. Cappelleri, Meghan Karuturi, Doris Makari, Lillian Shahied Arruda, Rickard Sandin, Kent A. Hanson, Justin Doan

palbociclib hormone receptor-positive HER2-negative hair loss endocrine therapy

TLDR Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.

The systematic review evaluated the impact of palbociclib on health-related quality of life (HRQoL) in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Analyzing 15 studies, including randomized controlled trials, single-arm trials, and real-world evidence, the review found that HRQoL was generally maintained or improved with palbociclib treatment. This included aspects like sexual functioning, hair loss upset, and systemic therapy side effects. The findings were consistent across various clinical characteristics and underrepresented populations, suggesting that palbociclib preserves HRQoL when added to endocrine therapy.

View this study on doi.org →

Discuss this study in the Community →

Similar Research

5 / 31 results

Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis

research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis

28 citations , July 2017 in “Expert Review of Anticancer Therapy”

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

research Patient, Oncologist, And Payer Preferences For Adjuvant Endocrine Therapy And CDK4/6 Inhibitor Regimens In Early-Stage Breast Cancer: A Discrete Choice Experiment

12 citations , March 2021 in “Patient Preference and Adherence”

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

4 citations , October 2018 in “Asia-Pacific Journal of Clinical Oncology”

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

research Efficacy and Safety of Trastuzumab Deruxtecan in the Treatment of HER2-Low/Positive Advanced Breast Cancer: A Single-Arm Meta-Analysis

13 citations , June 2023 in “Frontiers in Pharmacology”

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

research Cancer-Related Alopecia: From Etiologies to Global Management

4 citations , November 2021 in “Cancers”

The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.